| Dr John C Rausch, MD | |
|
3959 Broadway, Columbia Unversity Department Pediatric, New York, NY 10032-1559 | |
| (212) 304-7250 | |
| (212) 544-1974 |
| Full Name | Dr John C Rausch |
|---|---|
| Gender | Male |
| Speciality | Pediatrics |
| Location | 3959 Broadway, New York, New York |
| Accepts Medicare Assignments | Medicare enrolled and may accept medicare through third-party reassignment. May prescribe medicare part D drugs. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1093752263 | NPI | - | NPPES |
| 02779308 | Medicaid | NY |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 2083B0002X | Preventive Medicine - Obesity Medicine | 232241 (New York) | Secondary |
| 208000000X | Pediatrics | 232241 (New York) | Primary |
| Entity Name | Trustees Of Columbia University In The City Of New York |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1982993184 PECOS PAC ID: 8527972546 Enrollment ID: O20040407001360 |
News Archive
TSO3 Inc. is pleased to announce that it has filed a final short form prospectus with the securities regulatory authorities in all provinces of Canada with respect to a previously announced public offering of 10,000,000 common shares for gross proceeds to the Company of C$16 million. The prospectus also qualifies for the distribution of 150,000 Common shares sold by Simon Robitaille, one of the Company's founders and Chief Scientific Officer, for gross proceeds of $240,000.
Nymox Pharmaceutical Corporation is pleased to report positive new results from the 30-36 month follow-up study of patients treated with NX-1207 in Study NX02-0016. The initial study, completed in the U.S. in 2007, reached statistical significance in Intent-to-Treat Primary Efficacy outcomes at 90 days and 6 months post-treatment with NX-1207 2.5 mg.
The creatinine clearance (Ccr) test has been used as a gold standard for evaluation of preoperative renal function in patients with gastric cancer. However, it is known that Ccr is not strictly equivalent to glomerular filtration rate (GFR). It has been accepted that estimated GFR (eGFR) is equal to measured GFR in chronic kidney disease. However, there have been no studies regarding the reliability of eGFR as a preoperative renal function test in gastric cancer patients.
A recently discovered signaling system in the brain has just been shown to be turned on by methamphetamine, an Oregon Health & Science University study found.
› Verified 7 days ago
| Entity Name | Trustees Of Columbia University In The City Of New York |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1508266347 PECOS PAC ID: 8527972546 Enrollment ID: O20151201002613 |
News Archive
TSO3 Inc. is pleased to announce that it has filed a final short form prospectus with the securities regulatory authorities in all provinces of Canada with respect to a previously announced public offering of 10,000,000 common shares for gross proceeds to the Company of C$16 million. The prospectus also qualifies for the distribution of 150,000 Common shares sold by Simon Robitaille, one of the Company's founders and Chief Scientific Officer, for gross proceeds of $240,000.
Nymox Pharmaceutical Corporation is pleased to report positive new results from the 30-36 month follow-up study of patients treated with NX-1207 in Study NX02-0016. The initial study, completed in the U.S. in 2007, reached statistical significance in Intent-to-Treat Primary Efficacy outcomes at 90 days and 6 months post-treatment with NX-1207 2.5 mg.
The creatinine clearance (Ccr) test has been used as a gold standard for evaluation of preoperative renal function in patients with gastric cancer. However, it is known that Ccr is not strictly equivalent to glomerular filtration rate (GFR). It has been accepted that estimated GFR (eGFR) is equal to measured GFR in chronic kidney disease. However, there have been no studies regarding the reliability of eGFR as a preoperative renal function test in gastric cancer patients.
A recently discovered signaling system in the brain has just been shown to be turned on by methamphetamine, an Oregon Health & Science University study found.
› Verified 7 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr John C Rausch, MD 3959 Broadway, Columbia Unversity Department Pediatric, New York, NY 10032-1559 Ph: (212) 304-7297 | Dr John C Rausch, MD 3959 Broadway, Columbia Unversity Department Pediatric, New York, NY 10032-1559 Ph: (212) 304-7250 |
News Archive
TSO3 Inc. is pleased to announce that it has filed a final short form prospectus with the securities regulatory authorities in all provinces of Canada with respect to a previously announced public offering of 10,000,000 common shares for gross proceeds to the Company of C$16 million. The prospectus also qualifies for the distribution of 150,000 Common shares sold by Simon Robitaille, one of the Company's founders and Chief Scientific Officer, for gross proceeds of $240,000.
Nymox Pharmaceutical Corporation is pleased to report positive new results from the 30-36 month follow-up study of patients treated with NX-1207 in Study NX02-0016. The initial study, completed in the U.S. in 2007, reached statistical significance in Intent-to-Treat Primary Efficacy outcomes at 90 days and 6 months post-treatment with NX-1207 2.5 mg.
The creatinine clearance (Ccr) test has been used as a gold standard for evaluation of preoperative renal function in patients with gastric cancer. However, it is known that Ccr is not strictly equivalent to glomerular filtration rate (GFR). It has been accepted that estimated GFR (eGFR) is equal to measured GFR in chronic kidney disease. However, there have been no studies regarding the reliability of eGFR as a preoperative renal function test in gastric cancer patients.
A recently discovered signaling system in the brain has just been shown to be turned on by methamphetamine, an Oregon Health & Science University study found.
› Verified 7 days ago
Dr. Robert Michael Lembo, MD Pediatrics Medicare: Not Enrolled in Medicare Practice Location: 462 1st Ave, New York, NY 10016 Phone: 212-263-6425 | |
Dr. Sean Michael Bailey, M.D. Pediatrics Medicare: Medicare Enrolled Practice Location: 530 1st Ave, Suite 7a, New York, NY 10016 Phone: 212-263-7477 | |
Dr. Diana Trevas Fleisher, Pediatrics Medicare: Medicare Enrolled Practice Location: 550 1st Ave, New York, NY 10016 Phone: 212-263-3293 Fax: 212-263-3522 | |
Dr. Rajdeep K Saini, M.D. Pediatrics Medicare: Not Enrolled in Medicare Practice Location: 15 Warren St, New York, NY 10007 Phone: 212-226-7666 Fax: 212-202-7988 | |
Dr. Nooralam Ahmad Rai, MD Pediatrics Medicare: Medicare Enrolled Practice Location: 3959 Broadway # Chc701, New York, NY 10032 Phone: 212-305-5122 Fax: 212-305-6103 | |
Deborah Valentine Shamsian, MD Pediatrics Medicare: Medicare Enrolled Practice Location: 21 W 86th St, New York, NY 10024 Phone: 212-304-5800 | |
Kara Alex-ann Beliard, MD Pediatrics Medicare: Medicare Enrolled Practice Location: 1468 Madison Ave, New York, NY 10029 Phone: 122-241-6936 |